vs
FMC CORP（FMC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
FMC CORP的季度营收约是Revvity的1.4倍（$1.1B vs $772.1M），Revvity净利率更高（12.7% vs -158.8%，领先171.6%），Revvity同比增速更快（5.9% vs -11.5%），FMC CORP自由现金流更多（$631.1M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 8.6%）
FMC公司是总部位于美国宾夕法尼亚州费城的化工制造企业，1883年创立之初以生产杀虫剂为主，后续逐步拓展业务至其他领域。二战期间曾为美国陆军部设计生产两栖履带登陆车，目前在全球拥有7000名员工，业务布局广泛。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FMC vs RVTY — 直观对比
营收规模更大
FMC
是对方的1.4倍
$772.1M
营收增速更快
RVTY
高出17.4%
-11.5%
净利率更高
RVTY
高出171.6%
-158.8%
自由现金流更多
FMC
多$469.3M
$161.8M
两年增速更快
RVTY
近两年复合增速
8.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $772.1M |
| 净利润 | $-1.7B | $98.4M |
| 毛利率 | 39.8% | — |
| 营业利润率 | -130.8% | 14.5% |
| 净利率 | -158.8% | 12.7% |
| 营收同比 | -11.5% | 5.9% |
| 净利润同比 | -10457.1% | 3.9% |
| 每股收益（稀释后） | $-13.77 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FMCRVTY
| Q4 25 | $1.1B | $772.1M | ||
| Q3 25 | $542.2M | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $791.4M | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $1.0B | $691.7M | ||
| Q1 24 | $918.0M | $649.9M |
净利润FMCRVTY
| Q4 25 | $-1.7B | $98.4M | ||
| Q3 25 | $-569.3M | $46.7M | ||
| Q2 25 | $66.7M | $53.9M | ||
| Q1 25 | $-15.5M | $42.2M | ||
| Q4 24 | $-16.3M | $94.6M | ||
| Q3 24 | $65.0M | $94.4M | ||
| Q2 24 | $295.1M | $55.4M | ||
| Q1 24 | $-2.7M | $26.0M |
毛利率FMCRVTY
| Q4 25 | 39.8% | — | ||
| Q3 25 | 23.8% | 53.6% | ||
| Q2 25 | 38.7% | 54.5% | ||
| Q1 25 | 40.0% | 56.5% | ||
| Q4 24 | 42.9% | — | ||
| Q3 24 | 36.3% | 56.3% | ||
| Q2 24 | 38.3% | 55.7% | ||
| Q1 24 | 37.0% | 54.6% |
营业利润率FMCRVTY
| Q4 25 | -130.8% | 14.5% | ||
| Q3 25 | -73.1% | 11.7% | ||
| Q2 25 | 12.0% | 12.6% | ||
| Q1 25 | 7.4% | 10.9% | ||
| Q4 24 | 19.2% | 16.3% | ||
| Q3 24 | 12.7% | 14.3% | ||
| Q2 24 | 6.0% | 12.4% | ||
| Q1 24 | 8.1% | 6.8% |
净利率FMCRVTY
| Q4 25 | -158.8% | 12.7% | ||
| Q3 25 | -105.0% | 6.7% | ||
| Q2 25 | 6.3% | 7.5% | ||
| Q1 25 | -2.0% | 6.4% | ||
| Q4 24 | -1.3% | 13.0% | ||
| Q3 24 | 6.1% | 13.8% | ||
| Q2 24 | 28.4% | 8.0% | ||
| Q1 24 | -0.3% | 4.0% |
每股收益（稀释后）FMCRVTY
| Q4 25 | $-13.77 | $0.86 | ||
| Q3 25 | $-4.52 | $0.40 | ||
| Q2 25 | $0.53 | $0.46 | ||
| Q1 25 | $-0.12 | $0.35 | ||
| Q4 24 | $-0.13 | $0.77 | ||
| Q3 24 | $0.52 | $0.77 | ||
| Q2 24 | $2.35 | $0.45 | ||
| Q1 24 | $-0.02 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $584.5M | $919.9M |
| 总债务越低越好 | $3.4B | — |
| 股东权益账面价值 | $2.1B | $7.3B |
| 总资产 | $9.7B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.62× | — |
8季度趋势，按日历期对齐
现金及短期投资FMCRVTY
| Q4 25 | $584.5M | $919.9M | ||
| Q3 25 | $497.7M | $931.4M | ||
| Q2 25 | $438.2M | $991.8M | ||
| Q1 25 | $315.3M | $1.1B | ||
| Q4 24 | $357.3M | $1.2B | ||
| Q3 24 | $416.7M | $1.2B | ||
| Q2 24 | $471.5M | $2.0B | ||
| Q1 24 | $417.8M | $1.7B |
总债务FMCRVTY
| Q4 25 | $3.4B | — | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.4B | — | ||
| Q1 25 | $3.1B | — | ||
| Q4 24 | $3.1B | — | ||
| Q3 24 | $3.1B | — | ||
| Q2 24 | $3.1B | — | ||
| Q1 24 | $3.1B | — |
股东权益FMCRVTY
| Q4 25 | $2.1B | $7.3B | ||
| Q3 25 | $3.8B | $7.4B | ||
| Q2 25 | $4.4B | $7.6B | ||
| Q1 25 | $4.4B | $7.6B | ||
| Q4 24 | $4.5B | $7.7B | ||
| Q3 24 | $4.6B | $7.9B | ||
| Q2 24 | $4.6B | $7.9B | ||
| Q1 24 | $4.3B | $7.8B |
总资产FMCRVTY
| Q4 25 | $9.7B | $12.2B | ||
| Q3 25 | $12.1B | $12.1B | ||
| Q2 25 | $12.3B | $12.4B | ||
| Q1 25 | $11.8B | $12.4B | ||
| Q4 24 | $11.7B | $12.4B | ||
| Q3 24 | $12.2B | $12.8B | ||
| Q2 24 | $12.1B | $13.4B | ||
| Q1 24 | $12.0B | $13.4B |
负债/权益比FMCRVTY
| Q4 25 | 1.62× | — | ||
| Q3 25 | 0.89× | — | ||
| Q2 25 | 0.76× | — | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | 0.69× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.68× | — | ||
| Q1 24 | 0.72× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $631.1M | $161.8M |
| 自由现金流率自由现金流/营收 | 58.3% | 21.0% |
| 资本支出强度资本支出/营收 | 2.4% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-102.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流FMCRVTY
| Q4 25 | $657.1M | $182.0M | ||
| Q3 25 | $-184.2M | $138.5M | ||
| Q2 25 | $65.9M | $134.3M | ||
| Q1 25 | $-545.0M | $128.2M | ||
| Q4 24 | $427.9M | $174.2M | ||
| Q3 24 | $159.5M | $147.9M | ||
| Q2 24 | $292.2M | $158.6M | ||
| Q1 24 | $-142.9M | $147.6M |
自由现金流FMCRVTY
| Q4 25 | $631.1M | $161.8M | ||
| Q3 25 | $-207.9M | $120.0M | ||
| Q2 25 | $50.9M | $115.5M | ||
| Q1 25 | $-576.6M | $112.2M | ||
| Q4 24 | $406.3M | $149.8M | ||
| Q3 24 | $143.8M | $125.6M | ||
| Q2 24 | $282.3M | $136.6M | ||
| Q1 24 | $-163.6M | $129.7M |
自由现金流率FMCRVTY
| Q4 25 | 58.3% | 21.0% | ||
| Q3 25 | -38.3% | 17.2% | ||
| Q2 25 | 4.8% | 16.0% | ||
| Q1 25 | -72.9% | 16.9% | ||
| Q4 24 | 33.2% | 20.5% | ||
| Q3 24 | 13.5% | 18.4% | ||
| Q2 24 | 27.2% | 19.7% | ||
| Q1 24 | -17.8% | 20.0% |
资本支出强度FMCRVTY
| Q4 25 | 2.4% | 2.6% | ||
| Q3 25 | 4.4% | 2.6% | ||
| Q2 25 | 1.4% | 2.6% | ||
| Q1 25 | 4.0% | 2.4% | ||
| Q4 24 | 1.8% | 3.4% | ||
| Q3 24 | 1.5% | 3.3% | ||
| Q2 24 | 1.0% | 3.2% | ||
| Q1 24 | 2.3% | 2.7% |
现金转化率FMCRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 0.99× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 2.45× | 1.57× | ||
| Q2 24 | 0.99× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FMC
| Insecticides | $440.3M | 41% |
| Herbicides | $378.8M | 35% |
| Fungicides | $140.4M | 13% |
| Plant Health | $65.6M | 6% |
| Other | $45.0M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
